Needham & Company analyst Chad Messer said they would be buyers of Esperion Therapeutics (NASDAQ: ESPR) on today's weakness. The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE